Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Weill Cornell Medicine Qatar, Doha, Qatar.
Drug Discov Today. 2021 Jul;26(7):1669-1679. doi: 10.1016/j.drudis.2021.04.004. Epub 2021 Apr 20.
Current therapeutic approaches for diabetes are focused on improving glycemic control to prevent diabetes-related complications, but such approached are not completely successful. Decoy technologies such as decoy oligodeoxynucleotides (ODNs) and decoy peptides have emerged as therapeutic tools in diabetes. Decoy ODNs carry a DNA recognition motif for the binding of transcription factors in order to trap them and block their effects, whereas decoy peptides mimic the binding structure of the receptor protein, bind to the docking site of the target ligand, and prevent the interaction of the ligand and receptor. This review summarizes the technologies that have been developed to date and the studies that have investigated the therapeutic effects of decoy ODNs and peptides in diabetes.
目前治疗糖尿病的方法主要集中在改善血糖控制以预防糖尿病相关并发症上,但这些方法并非完全有效。诱饵技术,如诱饵寡核苷酸(ODN)和诱饵肽,已成为糖尿病治疗的工具。诱饵 ODN 携带 DNA 识别基序,用于结合转录因子以将其捕获并阻断其作用,而诱饵肽模拟受体蛋白的结合结构,与靶配体的对接位点结合,并防止配体与受体的相互作用。本综述总结了迄今为止开发的技术以及研究诱饵 ODN 和肽在糖尿病中的治疗效果的研究。